TRPA1: A promising target for pulmonary fibrosis?

Eur J Pharmacol. 2023 Nov 15:959:176088. doi: 10.1016/j.ejphar.2023.176088. Epub 2023 Sep 28.

Abstract

Pulmonary fibrosis is a disease characterized by progressive scar formation and the ultimate manifestation of numerous lung diseases. It is known as "cancer that is not cancer" and has attracted widespread attention. However, its formation process is very complex, and the mechanism of occurrence has not been fully elucidated. Current research has found that TRPA1 may be a promising target in the pathogenesis of pulmonary fibrosis. The TRPA1 channel was first successfully isolated in human lung fibroblasts, and it was found to have a relatively concentrated distribution in the lungs and respiratory tract. It is also involved in various acute and chronic inflammatory processes of lung diseases and may even play a core role in the progression and/or prevention of pulmonary fibrosis. Natural ligands targeting TRPA1 could offer a promising alternative treatment for pulmonary diseases. Therefore, this review delves into the current understanding of pulmonary fibrogenesis, analyzes TRPA1 biological properties and regulation of lung disease with a focus on pulmonary fibrosis, summarizes the TRPA1 molecular structure and its biological function, and summarizes TRPA1 natural ligand sources, anti-pulmonary fibrosis activity and potential mechanisms. The aim is to decipher the exact role of TRPA1 channels in the pathophysiology of pulmonary fibrosis and to consider their potential in the development of new therapeutic strategies.

Keywords: Fibroblasts; Natural ligands; Pulmonary fibrosis; TRPA1.

Publication types

  • Review

MeSH terms

  • Fibrosis
  • Humans
  • Inflammation / pathology
  • Lung / pathology
  • Pulmonary Fibrosis* / pathology
  • TRPA1 Cation Channel

Substances

  • TRPA1 Cation Channel
  • TRPA1 protein, human